MediciNova (NASDAQ:MNOV) has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of alcohol use disorder.
Once issued, the patent is expected to expire no earlier than May 2037.
In addition alcohol use disorder, the allowed claims also cover a method of treating a patients that exhibits symptoms of depression with ibudilast.
The allowed claims cover a wide range of dosage strengths and dosing regimens of MN-166 and combination therapies of ibudilast and one or more other therapeutic agents.